SAT0704-HPR PREVALENCE OF RHEUMATIC PATHOLOGY IN CHILDREN IN THE CENTRAL FEDERAL DISTRICT OF THE RUSSIAN FEDERATION, STRUCTURE OF MORBIDITY AND THERAPY-Reference-Cited by-同舟云学术

SAT0704-HPR PREVALENCE OF RHEUMATIC PATHOLOGY IN CHILDREN IN THE CENTRAL FEDERAL DISTRICT OF THE RUSSIAN FEDERATION, STRUCTURE OF MORBIDITY AND THERAPY

Published:2019-05-27 Issue: Volume: Page:
ISSN:
Container-title:HPR Epidemiology and public health (including prevention)
language:
Short-container-title:

Author:

Sevostyanov Vladislav,Zholobova Elena,Golubeva Alla,Baranova Olga,Poyemshina Kristina,Polukhina Anna

Publisher

BMJ Publishing Group Ltd and European League Against Rheumatism

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study;RMD Open;2022-02

2. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial;Annals of the Rheumatic Diseases;2021-01-27

3. Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis;RMD Open;2021-01

4. Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis;Annals of the Rheumatic Diseases;2020-11-04

5. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme;RMD Open;2020-10